TORONTO, The Globe and Mail (Ontario Edition) – One of Canada’s most celebrated scientists is bringing her new discovery to market, a pain-reducing alternative to opioids. AmacaThera Inc., spun out of a U of T lab, has raised millions from …
Trending at Lumira Ventures
AmacaThera’s Co-founder and CSO Dr. Molly Shoichet receives Canada’s most prestigious honour for breakthroughs in regenerative medicine.
OTTAWA, ON, Nov. 10, 2020 /CNW/ – The world is shining the spotlight on science now more than ever as we face the challenges of the COVID-19 pandemic. As Canadian science and engineering researchers continue to lead on the world …
AmacaThera to commence Phase 1 clinical trial for non-opioid, post-operative pain management.
TORONTO, Oct. 20, 2020 /PRNewswire – AmacaThera Inc. is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain. “This huge …
AmacaThera Closes US$3.6 Million Seed Financing Round
TORONTO, Oct. 3, 2019 / PRNewswire/ — AmacaThera Inc. is pleased to announce the closing of its US$3.6 million seed financing round. A first close of the round was led by Sprout BioVentures/Viva Biotech with participation from Grey Sky Venture Partners, and the round was …